drugset / Trial / NCT03203876
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors
Timeline
- Start
- 2017-07-14
- Primary completion
- 2020-08-06
- Completion
- 2020-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Lirilumab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |